Primary responsibilities include authorizations processes for inpatient and outpatient cellular and gene therapy services; and pricing changes for cellular therapy products; overseeing purchase orders and financial reconciliation; providing guidance on wholesale acquisition cost (WAC) and 340B pricing strategies; evaluating reimbursement considerations for clinical trials and commercial therapies; and serving as the primary financial liaison with pharmaceutical manufacturers, payers, and institutional stakeholders. Working collaboratively with program director, program manager, physicians, advanced practice providers, nursing, apheresis, pharmacy, social work, revenue cycle, finance, contracting, compliance, and other interdisciplinary stakeholders, this position advances operational excellence, financial stewardship, and program growth within a rapidly evolving cell and gene therapy landscape.